Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities.

Veal GJ, Amankwatia EB, Paludetto MN, Möcklinghoff T, Thomson F, André N, Ciccolini J, Chatelut E.

Ther Drug Monit. 2019 Apr;41(2):142-159. doi: 10.1097/FTD.0000000000000606.

PMID:
30883508
2.

Can Cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?

Peters GJ, Giovannetti E, Honeywell RJ, Ciccolini J.

Br J Clin Pharmacol. 2019 Mar 13. doi: 10.1111/bcp.13921. [Epub ahead of print] No abstract available.

PMID:
30866103
3.

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors.

Centanni M, Moes DJAR, Trocóniz IF, Ciccolini J, van Hasselt JGC.

Clin Pharmacokinet. 2019 Feb 28. doi: 10.1007/s40262-019-00748-2. [Epub ahead of print] Review.

PMID:
30815848
4.

From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer.

Rodallec A, Sicard G, Giacometti S, Carré M, Pourroy B, Bouquet F, Savina A, Lacarelle B, Ciccolini J, Fanciullino R.

Int J Nanomedicine. 2018 Oct 23;13:6677-6688. doi: 10.2147/IJN.S179290. eCollection 2018. Erratum in: Int J Nanomedicine. 2018 Dec 31;14:335.

5.

Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles.

Rodallec A, Sicard G, Fanciullino R, Benzekry S, Lacarelle B, Milano G, Ciccolini J.

Expert Opin Drug Metab Toxicol. 2018 Nov;14(11):1139-1147. doi: 10.1080/17425255.2018.1540588. Epub 2018 Oct 29. Review.

6.

Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring.

Moeung S, Chevreau C, Poinsignon V, Guitton J, Lelièvre B, Ciccolini J, Gladieff L, Massart C, Fléchon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Delahousse J, Filleron T, Lochon I, Chatelut E, Thomas F.

Ther Drug Monit. 2019 Feb;41(1):66-74. doi: 10.1097/FTD.0000000000000569.

PMID:
30299429
7.

[5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer].

Lemaitre F, Goirand F, Launay M, Chatelut E, Boyer JC, Evrard A, Paludetto MN, Guilhaumou R, Ciccolini J, Schmitt A.

Bull Cancer. 2018 Sep;105(9):790-803. doi: 10.1016/j.bulcan.2018.06.008. Epub 2018 Aug 10. Review. French.

8.

Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology.

Rodallec A, Benzekry S, Lacarelle B, Ciccolini J, Fanciullino R.

Crit Rev Oncol Hematol. 2018 Sep;129:1-12. doi: 10.1016/j.critrevonc.2018.06.008. Epub 2018 Jun 19. Review.

PMID:
30097227
9.

Predicting fluoropyrimidine-related toxicity: turning wish to will, the PAMM-EORTC position.

Ciccolini J, Del Re M, Danesi R, Milano G, Schellens JHM, Raymond E.

Ann Oncol. 2018 Sep 1;29(9):1893-1894. doi: 10.1093/annonc/mdy258. No abstract available.

PMID:
30032203
10.

Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.

Rodallec A, Brunel JM, Giacometti S, Maccario H, Correard F, Mas E, Orneto C, Savina A, Bouquet F, Lacarelle B, Ciccolini J, Fanciullino R.

Int J Nanomedicine. 2018 Jun 18;13:3451-3465. doi: 10.2147/IJN.S162454. eCollection 2018.

11.

"No pain, No gain" still true with immunotherapy: When the finger shows the moon, look at the moon!

Milano G, Innocenti F, Lacarelle B, Ciccolini J.

Crit Rev Oncol Hematol. 2018 Jul;127:1-5. doi: 10.1016/j.critrevonc.2018.04.003. Epub 2018 Apr 17. Review.

PMID:
29891106
12.

Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles.

Rodallec A, Fanciullino R, Lacarelle B, Ciccolini J.

Expert Rev Clin Pharmacol. 2018 Jun;11(6):599-610. doi: 10.1080/17512433.2018.1477586. Epub 2018 May 24. Review.

PMID:
29768060
13.

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

Boyer A, Pasquier E, Tomasini P, Ciccolini J, Greillier L, Andre N, Barlesi F, Mascaux C.

Eur Respir Rev. 2018 Mar 14;27(147). pii: 170098. doi: 10.1183/16000617.0098-2017. Print 2018 Mar 31. Review.

14.

CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine.

Fanciullino R, Farnault L, Donnette M, Imbs DC, Roche C, Venton G, Berda-Haddad Y, Ivanov V, Ciccolini J, Ouafik L, Lacarelle B, Costello R.

Blood Adv. 2018 Mar 13;2(5):462-469. doi: 10.1182/bloodadvances.2017014126. Erratum in: Blood Adv. 2018 May 8;2(9):1013.

15.

[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].

Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, Etienne-Grimaldi MC.

Bull Cancer. 2018 Apr;105(4):397-407. doi: 10.1016/j.bulcan.2018.02.001. Epub 2018 Feb 24. Review. French.

16.

Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma.

Imbs DC, El Cheikh R, Boyer A, Ciccolini J, Mascaux C, Lacarelle B, Barlesi F, Barbolosi D, Benzekry S.

CPT Pharmacometrics Syst Pharmacol. 2018 Jan;7(1):42-50. doi: 10.1002/psp4.12265. Epub 2017 Dec 7.

17.

PRIMUM NON NOCERE: now and again an echo of DPD with capecitabine.

Ciccolini J, Lacarelle B, Milano G.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1265-1266. doi: 10.1007/s00280-017-3437-z. Epub 2017 Oct 13. No abstract available.

PMID:
29030673
18.

Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study.

Moeung S, Chevreau C, Broutin S, Guitton J, Lelièvre B, Ciccolini J, Massart C, Fléchon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Paci A, Marsili S, Malard L, Chatelut E, Thomas F.

Clin Cancer Res. 2017 Dec 1;23(23):7171-7179. doi: 10.1158/1078-0432.CCR-17-1344. Epub 2017 Sep 19.

19.

Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing.

Etienne-Grimaldi MC, Le Guellec CB, Boyer JC, Chatelut E, Evrard A, Loriot MA, Paci A, Royer B, Thomas F, Ciccolini J.

Semin Oncol. 2017 Apr;44(2):159-160. doi: 10.1053/j.seminoncol.2017.06.001. Epub 2017 Jul 4. No abstract available.

PMID:
28923215
20.

Pharmacokinetics and Pharmacodynamics-Based Mathematical Modeling Identifies an Optimal Protocol for Metronomic Chemotherapy.

Ciccolini J, Barbolosi D, Meille C, Lombard A, Serdjebi C, Giacometti S, Padovani L, Pasquier E, André N.

Cancer Res. 2017 Sep 1;77(17):4723-4733. doi: 10.1158/0008-5472.CAN-16-3130. Epub 2017 Jun 27.

21.

A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients.

Becher F, Ciccolini J, Imbs DC, Marin C, Fournel C, Dupuis C, Fakhry N, Pourroy B, Ghettas A, Pruvost A, Junot C, Duffaud F, Lacarelle B, Salas S.

Sci Rep. 2017 Jun 2;7(1):2714. doi: 10.1038/s41598-017-02821-x.

22.

Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients.

Barlesi F, Imbs DC, Tomasini P, Greillier L, Galloux M, Testot-Ferry A, Garcia M, Elharrar X, Pelletier A, André N, Mascaux C, Lacarelle B, Cheikh RE, Serre R, Ciccolini J, Barbolosi D.

Oncotarget. 2017 Jul 18;8(29):47161-47166. doi: 10.18632/oncotarget.17562.

23.

Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis.

Mollard S, Ciccolini J, Imbs DC, El Cheikh R, Barbolosi D, Benzekry S.

Oncotarget. 2017 Apr 4;8(14):23087-23098. doi: 10.18632/oncotarget.15484.

24.

Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach.

Serdjebi C, Gattacceca F, Seitz JF, Fein F, Gagnière J, François E, Abakar-Mahamat A, Deplanque G, Rachid M, Lacarelle B, Ciccolini J, Dahan L.

Ther Drug Monit. 2017 Jun;39(3):290-296. doi: 10.1097/FTD.0000000000000399.

PMID:
28346313
25.

UPFRONT DPD DEFICIENCY DETECTION TO SECURE 5-FU ADMINISTRATION: PART 2- APPLICATION TO HEAD-AND-NECK CANCER PATIENTS.

Launay M, Ciccolini J, Fournel C, Blanquicett C, Dupuis C, Fakhry N, Duffaud F, Salas S, Lacarelle B.

Clin Cancer Drugs. 2017;4(2):122-128. doi: 10.2174/2212697x04666170817123425.

26.

In Vivo Bioluminescence Tomography for Monitoring Breast Tumor Growth and Metastatic Spreading: Comparative Study and Mathematical Modeling.

Mollard S, Fanciullino R, Giacometti S, Serdjebi C, Benzekry S, Ciccolini J.

Sci Rep. 2016 Nov 4;6:36173. doi: 10.1038/srep36173.

27.

Dose Effect of Rhenium (I)-diselenoether as Anticancer Drug in Resistant Breast Tumor-bearing Mice After Repeated Administrations.

Collery P, Santoni F, Ciccolini J, Tran TN, Mohsen A, Desmaele D.

Anticancer Res. 2016 Nov;36(11):6051-6057.

PMID:
27793932
28.

Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck?

Danesi R, Del Re M, Ciccolini J, Schellens JHM, Schwab M, van Schaik RHN, van Kuilenburg ABP.

Ann Oncol. 2017 Jan 1;28(1):183. doi: 10.1093/annonc/mdw448. No abstract available.

PMID:
27687313
29.

Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine.

Gouri A, Dekaken A, El Bairi K, Aissaoui A, Laabed N, Chefrour M, Ciccolini J, Milano G, Benharkat S.

Biomark Insights. 2016 Aug 16;11:105-11. doi: 10.4137/BMI.S33372. eCollection 2016. Review.

30.

Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy.

Serre R, Benzekry S, Padovani L, Meille C, André N, Ciccolini J, Barlesi F, Muracciole X, Barbolosi D.

Cancer Res. 2016 Sep 1;76(17):4931-40. doi: 10.1158/0008-5472.CAN-15-3567. Epub 2016 Jun 14.

31.

Women at a Disadvantage in Fluorouracil Treatment.

Ciccolini J, Milano G.

JAMA Oncol. 2016 Jun 1;2(6):829-30. doi: 10.1001/jamaoncol.2016.1086. No abstract available.

PMID:
27281624
32.

Nucleoside analogs: ready to enter the era of precision medicine?

Ciccolini J, Serdjebi C, Le Thi Thu H, Lacarelle B, Milano G, Fanciullino R.

Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):865-77. doi: 10.1080/17425255.2016.1192128. Epub 2016 May 30. Review.

PMID:
27218825
33.

A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol.

Elharrar X, Barbolosi D, Ciccolini J, Meille C, Faivre C, Lacarelle B, André N, Barlesi F.

BMC Cancer. 2016 Apr 20;16:278. doi: 10.1186/s12885-016-2308-z.

34.

An alternative parameter for early forecasting clinical response in NSCLC patients during radiotherapy: proof of concept study.

Padovani L, Baret A, Ciccolini J, Taieb D, Bardia F, Teissonnier L, Muracciole X, Barlesi F, Barbolosi D.

Br J Radiol. 2016 Jun;89(1062):20160061. doi: 10.1259/bjr.20160061. Epub 2016 Apr 4.

35.

Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective.

Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E.

Cancer Chemother Pharmacol. 2016 Jul;78(1):1-12. doi: 10.1007/s00280-016-3003-0. Epub 2016 Mar 23. Review.

36.

Monoclonal antibodies for treating gastric cancer: promises and pitfalls.

Sibertin-Blanc C, Ciccolini J, Norguet E, Lacarelle B, Dahan L, Seitz JF.

Expert Opin Biol Ther. 2016 Jun;16(6):759-69. doi: 10.1517/14712598.2016.1164137. Epub 2016 Mar 25. Review.

PMID:
26971395
37.

Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy.

Meille C, Barbolosi D, Ciccolini J, Freyer G, Iliadis A.

Clin Pharmacokinet. 2016 Aug;55(8):1015-25. doi: 10.1007/s40262-016-0374-7.

PMID:
26946136
38.

DPD deficiency in patients treated with fluorouracil.

Ciccolini J.

Lancet Oncol. 2015 Dec;16(16):1574-6. doi: 10.1016/S1470-2045(15)00360-5. Epub 2015 Oct 23. No abstract available.

PMID:
26603944
39.

Computational oncology--mathematical modelling of drug regimens for precision medicine.

Barbolosi D, Ciccolini J, Lacarelle B, Barlési F, André N.

Nat Rev Clin Oncol. 2016 Apr;13(4):242-54. doi: 10.1038/nrclinonc.2015.204. Epub 2015 Nov 24. Review.

PMID:
26598946
40.

Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics tale.

Fanciullino R, Mercier C, Serdjebi C, Venton G, Colle J, Fina F, Ouafik L, Lacarelle B, Ciccolini J, Costello R.

Pharmacogenomics. 2015 Nov;16(17):1907-12. doi: 10.2217/pgs.15.135. Epub 2015 Nov 10.

PMID:
26556583
41.

Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.

Launay M, Dahan L, Duval M, Rodallec A, Milano G, Duluc M, Lacarelle B, Ciccolini J, Seitz JF.

Br J Clin Pharmacol. 2016 Jan;81(1):124-30. doi: 10.1111/bcp.12790. Epub 2015 Nov 28.

42.

Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.

Benzekry S, Pasquier E, Barbolosi D, Lacarelle B, Barlési F, André N, Ciccolini J.

Semin Cancer Biol. 2015 Dec;35:53-61. doi: 10.1016/j.semcancer.2015.09.002. Epub 2015 Sep 7. Review.

PMID:
26361213
43.

FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.

Serdjebi C, Gagnière J, Desramé J, Fein F, Guimbaud R, François E, André T, Seitz JF, Montérymard C, Arsene D, Volet J, Abakar-Mahamat A, Lecomte T, Guerin-Meyer V, Legoux JL, Deplanque G, Guillet P, Ciccolini J, Lepage C, Dahan L.

PLoS One. 2015 Aug 26;10(8):e0135907. doi: 10.1371/journal.pone.0135907. eCollection 2015.

44.

Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support.

Ciccolini J, Benzekry S, Lacarelle B, Barbolosi D, Barlési F.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3453. doi: 10.1073/pnas.1506689112. Epub 2015 Jun 16. No abstract available.

45.

Eradication of T315I mutation in chronic myeloid leukemia without third-generation tyrosine kinase inhibitor: a case report.

Venton G, Colle J, Mercier C, Fanciullino R, Ciccolini J, Ivanov V, Suchon P, Sebahoun G, Beaufils N, Gabert J, Hadjaj D, Costello R.

Pharmacogenomics. 2015;16(7):677-9. doi: 10.2217/pgs.15.25. Epub 2015 May 7.

PMID:
25950190
46.

Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.

Fanciullino R, Mercier C, Serdjebi C, Berda Y, Fina F, Ouafik L, Lacarelle B, Ciccolini J, Costello R.

Pharmacogenet Genomics. 2015 Jun;25(6):317-21. doi: 10.1097/FPC.0000000000000139.

PMID:
25850965
47.

Ang1 and Tie2 are predictive biomarkers for bevacizumab-letter.

Ciccolini J, Serdjebi C, Barbolosi D, Lacarelle B, Barlesi F.

Clin Cancer Res. 2015 Feb 15;21(4):934. doi: 10.1158/1078-0432.CCR-14-2832. No abstract available.

48.

Pharmacogenetics and breast cancer management: current status and perspectives.

Ciccolini J, Fanciullino R, Serdjebi C, Milano G.

Expert Opin Drug Metab Toxicol. 2015 May;11(5):719-29. doi: 10.1517/17425255.2015.1008447. Epub 2015 Feb 18. Review.

PMID:
25690018
49.

Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs.

Serdjebi C, Milano G, Ciccolini J.

Expert Opin Drug Metab Toxicol. 2015 May;11(5):665-72. doi: 10.1517/17425255.2015.985648. Epub 2014 Dec 13. Review.

PMID:
25495470
50.

Trastuzumab-induced cardiotoxicity: is it a personalized risk?

Milano GA, Serres E, Ferrero JM, Ciccolini J.

Curr Drug Targets. 2014;15(13):1200-4. Review.

PMID:
25395105

Supplemental Content

Loading ...
Support Center